Parkside Financial Bank & Trust Novavax Inc Transaction History

Parkside Financial Bank & Trust

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 13, 2022	BUY	$36.28 - $75.29 $1,632 - $3,388	45 New	45 $2,000
Q1 2022 May 13, 2022	SELL	$69.73 - $142.9 $1,394 - $2,858	-20 Closed	0 $0
Q3 2021 Oct 29, 2021	BUY	$177.8 - $270.58 $2,489 - $3,788	14 Added 233.33%	20 $4,000
Q2 2021 Aug 06, 2021	SELL	$121.0 - $257.67 $2,904 - $6,184	-24 Reduced 80.0%	6 $1,000
Q1 2021 May 10, 2021	SELL	$112.98 - $319.93 $1,355 - $3,839	-12 Reduced 28.57%	30 $5,000
Q4 2020 Feb 09, 2021	SELL	$78.74 - $139.5 $12,047 - $21,343	-153 Reduced 78.46%	42 $5,000
Q3 2020 Nov 06, 2020	BUY	$79.44 - $178.51 $3,336 - $7,497	42 Added 27.45%	195 $21,000
Q2 2020 Aug 10, 2020	BUY	$13.86 - $83.61 $2,120 - $12,792	153 New	153 $13,000

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $662M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Parkside Financial Bank & Trust, based on Form 13F filings with the SEC.

Stay updated on Parkside Financial Bank & Trust with notifications on news.